glp 1 agonist review article GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Glucagon-like peptide 1 receptor agonists:

This imbalance did not affect the primary endpoint and the incidence rate was higher in patients with a previous history of heart failure and independent of renal function at study baseline (57, 66, 67)

With more than 150 published papers and book chapters on obesity and its treatment, Dr

Its also important to screen for any history of eating disorders, as the appetite-suppressing effects of GLP-1s may pose risks for certain individuals

The correlation between the anti-inflammatory properties of GLP-1RA and clinical outcomes need more research

Now used for medical weight loss, Semaglutide GLP-1 injections are very popular

This will be a huge field, Moore